TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32583557

Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 34

Group type: COMPARATOR
Intervention: Investigator's choice of therapy (IC)
Number of subjects: 34
Study: 33973051

Group type: EXPERIMENTAL
Intervention: Double Balloon Catheter (DBC)
Number of subjects: 420

Group type: COMPARATOR
Intervention: Prostaglandin Pessary (PGE)
Number of subjects: 420
Study: 33761288

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) - 2 sessions per week for 12 weeks, consisting of 40 minutes of treadmill running/walking including warm-up, high-intensity intervals, and cool-down.
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control group (CG) - no intense exercise during the intervention period.
Number of subjects: 140
Study: 33093616

Group type: EXPERIMENTAL
Intervention: Intensive group patients with DBP ≤ 70 mmHg (SPRINT trial)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intensive group patients with DBP ≤ 70 mmHg (ACCORD trial)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Different SBP/DBP levels (CKD patients in SPRINT trial)
Number of subjects: 0
Study: 33542383

Group type: EXPERIMENTAL
Intervention: Dual n-back training (NBG)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Method of loci training (MPG)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Blank control group (BCG)
Number of subjects: 148
Study: 36050256

Group type: EXPERIMENTAL
Intervention: Ipswich Touch Test (IpTT)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Standard Monofilament Test (SMT)
Number of subjects: 8
Study: 34128810

Group type: EXPERIMENTAL
Intervention: Active conditions (intervention)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Passive controls (no treatment or waitlist)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: MAR-based multiple imputation or maximum likelihood methods
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Sensitivity analysis approaches (pattern‐mixture model and fixed‐value replacement)
Number of subjects: 36
Study: 35404691

Group type: EXPERIMENTAL
Intervention: Superimposed high-frequency jet ventilation (SHFJV)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional high-frequency jet ventilation (CHFJV)
Number of subjects: 60
Study: 32829060

Group type: EXPERIMENTAL
Intervention: Specially processed cereals (SPC)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Intravenous glycerol and dexamethasone
Number of subjects: 26
Study: 36104143

Group type: EXPERIMENTAL
Intervention: Intracapsular microdebrider tonsillectomy
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Intracapsular coblation tonsillectomy
Number of subjects: 200

Group type: COMPARATOR
Intervention: Extracapsular monopolar tonsillectomy
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: All surgical methods
Number of subjects: 200
Study: 33629614

Group type: EXPERIMENTAL
Intervention: Interactive 'dealing with uncertainty' seminars with statistical lessons and diagnostic reasoning
Number of subjects: 209

Group type: COMPARATOR
Intervention: Seminars without in-depth diagnostic lessons (control group)
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Interactive 'dealing with uncertainty' seminars
Number of subjects: 209
Study: 32519972

Group type: EXPERIMENTAL
Intervention: ViSi Mobile (VM)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: HealthPatch (HP)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study: 35675604

Group type: EXPERIMENTAL
Intervention: Relugolix combination therapy (relugolix-CT: relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg)
Number of subjects: 509

Group type: EXPERIMENTAL
Intervention: Relugolix combination therapy (relugolix-CT)
Number of subjects: 509

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 509
Study: 32572795

Group type: EXPERIMENTAL
Intervention: Strength training
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Awareness Through Movement®
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control group (usual everyday life)
Number of subjects: 3
Study: 35916920

Group type: EXPERIMENTAL
Intervention: Combination arm (RE + sorafenib)
Number of subjects: 177

Group type: COMPARATOR
Intervention: Sorafenib arm
Number of subjects: 177
Study: 35258271

Group type: COMPARATOR
Intervention: YMCA submaximal cycle test (YMCAT)
Number of subjects: 47

Group type: COMPARATOR
Intervention: 6-Minute Walk Test (6MWT)
Number of subjects: 47
Study: 32608353

Group type: EXPERIMENTAL
Intervention: REACT plus the resource directory (n=399)
Number of subjects: 800

Group type: COMPARATOR
Intervention: Resource directory only (n=401)
Number of subjects: 800
Study: 33202098

Group type: EXPERIMENTAL
Intervention: light + OLED
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: dark + OLED
Number of subjects: 119

Group type: COMPARATOR
Intervention: light + eINK
Number of subjects: 119

Group type: COMPARATOR
Intervention: dark + eINK
Number of subjects: 119
Study: 36051936

Group type: EXPERIMENTAL
Intervention: CT radiomics and clinical imaging features of the primary tumor
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Clinical imaging factors associated with bone metastases
Number of subjects: 195
Study: 33993727

Group type: EXPERIMENTAL
Intervention: Text message Nudges
Number of subjects: 400

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 400
Study: 32020756

Group type: EXPERIMENTAL
Intervention: Revascularisation in patients with symptoms and/or acute coronary syndromes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Revascularisation in asymptomatic patients with stable ischaemic heart disease
Number of subjects: 0
Study: 36135935

Group type: EXPERIMENTAL
Intervention: MH‐SR (500 mg/tablet)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Glucophage®‐XR (500 mg/tablet)
Number of subjects: 48
Study: 34805718

Group type: COMPARATOR
Intervention: RT plus placebo (P)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: RT plus investigational agent (A)
Number of subjects: 48
Study: 35981832

Group type: EXPERIMENTAL
Intervention: IVUS-guided optimization
Number of subjects: 291

Group type: COMPARATOR
Intervention: Control (standard of care)
Number of subjects: 291
Study: 32639170

Group type: EXPERIMENTAL
Intervention: Challenge-focused program targeted toward high autonomous motivation
Number of subjects: 15

Group type: COMPARATOR
Intervention: Rewards-focused program targeted toward low autonomous motivation
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Both programs
Number of subjects: 15
Study: 32768001

Group type: EXPERIMENTAL
Intervention: ECCO2R therapy for ARDS
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: ECCO2R therapy for ae‐COPD
Number of subjects: 14
Study: 35987076

Group type: EXPERIMENTAL
Intervention: Endovascular physiotherapy combined with acupuncture
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal group
Number of subjects: 40
Study: 33073847

Group type: EXPERIMENTAL
Intervention: Endovascular coiling
Number of subjects: 1644

Group type: COMPARATOR
Intervention: Neurosurgical clipping
Number of subjects: 1644
Study: 36297029

Group type: EXPERIMENTAL
Intervention: Spirulina supplementation (SP group, n = 20)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo supplementation (PB group, n = 19)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Spirulina supplementation (SP group)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Comparison between SP and PB groups
Number of subjects: 39
Study: 34967166

Group type: EXPERIMENTAL
Intervention: Longidaza 3000 ME therapy in combination with tamsulosin
Number of subjects: 120

Group type: COMPARATOR
Intervention: Tamsulosin monotherapy
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Longidaza 3000 ME therapy
Number of subjects: 120
Study: 35092722

Group type: EXPERIMENTAL
Intervention: Everolimus (7.5 mg daily for first 3 days, 5.0 mg daily for days 4 and 5)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 0
Study: 33368026

Group type: EXPERIMENTAL
Intervention: Combination viloxazine ER (700 mg) + methylphenidate (36 mg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Viloxazine ER (700 mg) alone
Number of subjects: 36

Group type: COMPARATOR
Intervention: Methylphenidate (36 mg) alone
Number of subjects: 36
Study: 33881745

Group type: EXPERIMENTAL
Intervention: Durvalumab after CRT
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 32068418

Group type: EXPERIMENTAL
Intervention: Female‐Specific Cognitive Behavioral Therapy (FS‐CBT)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Gender‐Neutral CBT (GN‐CBT)
Number of subjects: 99
Study: 34574642

Group type: EXPERIMENTAL
Intervention: Experimental group (diary reflection intervention)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 80
Study: 34261483

Group type: EXPERIMENTAL
Intervention: Low socioeconomic position (SEP)
Number of subjects: 1362

Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 1362

Group type: EXPERIMENTAL
Intervention: Ophthalmopathy
Number of subjects: 1362

Group type: EXPERIMENTAL
Intervention: Circulatory complications
Number of subjects: 1362

Group type: EXPERIMENTAL
Intervention: Institutional type
Number of subjects: 1362

Group type: EXPERIMENTAL
Intervention: Old age
Number of subjects: 1362
Study: 32027763

Group type: EXPERIMENTAL
Intervention: Adapted evidence-based intervention from U.S. for disruptive behavior disorders (DBDs) in Uganda, details on dosage and duration not available.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 32665034

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion (0.6 μg/kg for 10 min after central vein catheterization, followed by 0.4 μg/kg/h until the end of surgery)
Number of subjects: 652

Group type: COMPARATOR
Intervention: Placebo (normal saline administered at the same rate as dexmedetomidine)
Number of subjects: 652

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion
Number of subjects: 652

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 652
Study: 35906554

Group type: EXPERIMENTAL
Intervention: Opioid-free anesthesia with dexmedetomidine (loading dose 0.6 μg·kg−1 for 10 min, then 0.5 μg·kg−1·h−1 continuous infusion) and sevoflurane plus bilateral paravertebral blockade (0.2 μg·kg−1 dexmedetomidine and 0.5% ropivacaine 15 ml per side)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Opioid-based anesthesia with remifentanil, sevoflurane, and bilateral paravertebral blockade (0.5% ropivacaine 15 ml per side)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Opioid-free anesthesia
Number of subjects: 101

Group type: COMPARATOR
Intervention: Opioid-based anesthesia
Number of subjects: 101
Study: 33394929

Group type: EXPERIMENTAL
Intervention: Vergence/accommodative therapy
Number of subjects: 12

Group type: COMPARATOR
Intervention: Not applicable (control group)
Number of subjects: 12
Study: 32932395

Group type: EXPERIMENTAL
Intervention: Scleral Lens (SL) worn on one eye for 6 hours
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control eye (no scleral lens)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Diaton tonometry
Number of subjects: 26
Study: 35998132

Group type: EXPERIMENTAL
Intervention: Training-as-usual plus psychotherapy apprenticeship
Number of subjects: 120

Group type: COMPARATOR
Intervention: Training-as-usual
Number of subjects: 120
Study: 33857750

Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 34253602

Group type: EXPERIMENTAL
Intervention: Monitoring by a partner nongovernmental organization for 15 months with results disseminated to local and provincial governments.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Monitoring by a partner nongovernmental organization for 15 months with results disseminated to the public.
Number of subjects: 0
Study: 34202690

Group type: EXPERIMENTAL
Intervention: Home Meal Replacement (HMR)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control (regular dietary pattern)
Number of subjects: 64
Study: 32645771

Group type: EXPERIMENTAL
Intervention: Nitric Oxide (NO) administration during cardiopulmonary bypass (CPB)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo administration during cardiopulmonary bypass (CPB)
Number of subjects: 24
Study: 35255184

Group type: EXPERIMENTAL
Intervention: Shockwave therapy
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Radiofrequency
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 32967704

Group type: EXPERIMENTAL
Intervention: Transcutaneous vagus nerve stimulation (Nemos® tVNS), sham-controlled
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Motivational nondirective resonance breathing (MNRB™), sham-controlled
Number of subjects: 112
Study: 33935227

Group type: EXPERIMENTAL
Intervention: Self-Advocacy for Independent Life (SAIL) intervention
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 67
Study: 34083615

Group type: EXPERIMENTAL
Intervention: Anfibatide administered intravenously as a single dose bolus or a bolus followed by a constant rate infusion for 24 hours
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Anfibatide
Number of subjects: 94
Study: 34920734

Group type: EXPERIMENTAL
Intervention: Aspirin 75 mg once-daily
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Aspirin 300 mg once-daily
Number of subjects: 96

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: HbA1c levels > 65 mmol/mol
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: HbA1c levels > 70 mmol/mol
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Higher HbA1c
Number of subjects: 96
Study: 33501530

Group type: EXPERIMENTAL
Intervention: Full‐day leadership training retreat for team leaders to facilitate care team huddles, biweekly coaching calls, and two site visits with an assigned coach.
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Higher adherence to the intervention within the intervention group.
Number of subjects: 29

Group type: COMPARATOR
Intervention: Routine practice (control group).
Number of subjects: 29
Study: 36605352

Group type: EXPERIMENTAL
Intervention: Barbed sutures
Number of subjects: 60

Group type: COMPARATOR
Intervention: Tackers with transfacial sutures
Number of subjects: 60
Study: 33035194

Group type: EXPERIMENTAL
Intervention: Chronic pain and physical activity training workshop
Number of subjects: 48
Study: 32328239

Group type: EXPERIMENTAL
Intervention: Waist:Hip Ratio (WHR)
Number of subjects: 1709

Group type: EXPERIMENTAL
Intervention: Waist:Height Ratio (WHtR)
Number of subjects: 1709

Group type: EXPERIMENTAL
Intervention: Waist Circumference (WC)
Number of subjects: 1709

Group type: COMPARATOR
Intervention: Body Mass Index (BMI)
Number of subjects: 1709

Group type: COMPARATOR
Intervention: Body Fat Percentage and Fat per Square of Height
Number of subjects: 1709
Study: 36437191

Group type: EXPERIMENTAL
Intervention: Combined model incorporating clinical and PET features
Number of subjects: 271

Group type: COMPARATOR
Intervention: International Prognostic Index (IPI) model
Number of subjects: 271

Group type: COMPARATOR
Intervention: Best baseline clinical model
Number of subjects: 271

Group type: COMPARATOR
Intervention: Deauville score (DS) model
Number of subjects: 271

Group type: COMPARATOR
Intervention: Best combined clinical model
Number of subjects: 271

Group type: COMPARATOR
Intervention: Best PET-based radiomics model
Number of subjects: 271
Study: 33125609

Group type: EXPERIMENTAL
Intervention: Real tDCS
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 24
Study: 33541060

Group type: EXPERIMENTAL
Intervention: Sander bite jumping appliance (BJA)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Andresen activator (AA)
Number of subjects: 20
Study: 36131360

Group type: COMPARATOR
Intervention: Febuxostat 80 mg alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: SHR4640 10 mg alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SHR4640 combined with febuxostat
Number of subjects: 0
Study: 34837937

Group type: EXPERIMENTAL
Intervention: Pre-notification of the request for further information, sent 1 day before the request.
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (no pre-notification).
Number of subjects: 75
Study: 34970224

Group type: EXPERIMENTAL
Intervention: Low-Carbohydrate Diet (LCD)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Low-Fat Diet (LFD)
Number of subjects: 134
Study: 32114867

Group type: EXPERIMENTAL
Intervention: Training given to parents (5-week duration)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 75
Study: 33992100

Group type: EXPERIMENTAL
Intervention: Spinal manual therapy
Number of subjects: 43

Group type: COMPARATOR
Intervention: Local exercise therapy
Number of subjects: 43
Study: 32897437

Group type: EXPERIMENTAL
Intervention: HES 130/0.4/9
Number of subjects: 50

Group type: COMPARATOR
Intervention: 5% albumin
Number of subjects: 50
Study: 34472676

Group type: EXPERIMENTAL
Intervention: WEB+TXT (n=311)
Number of subjects: 618

Group type: COMPARATOR
Intervention: WEB (n=307)
Number of subjects: 618

Group type: EXPERIMENTAL
Intervention: WEB+TXT
Number of subjects: 618
Study: 33856430

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 377

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 377
Study: 32321172

Group type: EXPERIMENTAL
Intervention: Antithrombin (AT) supplementation
Number of subjects: 784

Group type: EXPERIMENTAL
Intervention: Fibrinogen concentrates
Number of subjects: 784

Group type: EXPERIMENTAL
Intervention: Fresh frozen plasma transfusion
Number of subjects: 784

Group type: EXPERIMENTAL
Intervention: Heparin prophylaxis
Number of subjects: 784

Group type: EXPERIMENTAL
Intervention: Prophylactic measures
Number of subjects: 784

Group type: EXPERIMENTAL
Intervention: L‐asparaginase (L‐ASP) therapy
Number of subjects: 784

Group type: EXPERIMENTAL
Intervention: L‐ASP reintroduction
Number of subjects: 784
Study: 35287591

Group type: EXPERIMENTAL
Intervention: sintilimab immunotherapy combined with XELOX chemotherapy
Number of subjects: 30
Study: 33559248

Group type: EXPERIMENTAL
Intervention: Completion of Donor Health Questionnaire (DHQ) and antibody testing
Number of subjects: 521

Group type: EXPERIMENTAL
Intervention: PCR testing for SARS-CoV-2
Number of subjects: 521

Group type: EXPERIMENTAL
Intervention: Antibody testing
Number of subjects: 521

Group type: EXPERIMENTAL
Intervention: Overall screening process
Number of subjects: 521
Study: 32922193

Group type: EXPERIMENTAL
Intervention: Ephedrine 20 mg intramuscularly
Number of subjects: 116

Group type: COMPARATOR
Intervention: 0.9% NaCl (saline)
Number of subjects: 116
Study: 34779837

Group type: EXPERIMENTAL
Intervention: Quality improvement intervention bundle including educational materials, clinical algorithm and order set for IVF use, electronic medical record interventions, and 'harms of overtesting' cards.
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Quality improvement intervention bundle
Number of subjects: 100
Study: 35010414

Group type: EXPERIMENTAL
Intervention: Mindfulness- and compassion-based program (MCBP for University Life)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 30
Study: 36026840

Group type: EXPERIMENTAL
Intervention: Ramipril 10 mg once daily
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Nifedipine gastrointestinal therapeutic system (GITS) 30 mg once daily
Number of subjects: 146

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 146
Study: 33514760

Group type: EXPERIMENTAL
Intervention: RRR‐α‐tocopherol (ALC) at doses of 50, 75, 100, and 150 mg/kg of diet
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: RRR‐α‐tocopheryl acetate (ACT)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: all‐rac‐α‐tocopheryl acetate (SYN)
Number of subjects: 168

Group type: COMPARATOR
Intervention: No added α‐tocopherol in the feed (0 dose)
Number of subjects: 168
Study: 34954095

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (daily HCQ)
Number of subjects: 624

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (weekly HCQ)
Number of subjects: 624

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 624
Study: 35902796

Group type: EXPERIMENTAL
Intervention: Eptinezumab 100 mg
Number of subjects: 238

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 238
Study: 33394005

Group type: EXPERIMENTAL
Intervention: Low-fat vegan diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 32493624

Group type: EXPERIMENTAL
Intervention: Tungsten carbide bur
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Fibreglass bur
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Polymer bur
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Polymer bur with 75% ethanol pre-treatment
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Polymer burs
Number of subjects: 28
Study: 36219925

Group type: EXPERIMENTAL
Intervention: Respiratory muscle training (RMT) with a threshold resistance device, daily, twice a day for three sets of 15 repetitions for 8 weeks
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (lifestyle modification education without RMT)
Number of subjects: 36
Study: 33761976

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (standard active rehabilitation)
Number of subjects: 42
Study: 32192925

Group type: EXPERIMENTAL
Intervention: Titanium-prepared platelet-rich fibrin (T-PRF)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Connective tissue graft (CTG)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study: 35636174

Group type: EXPERIMENTAL
Intervention: Parent-administered pediatric tuina
Number of subjects: 64

Group type: COMPARATOR
Intervention: Parent–child interaction group (control)
Number of subjects: 64
Study: 32526188

Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza vaccine (IIV)
Number of subjects: 10002

Group type: COMPARATOR
Intervention: Saline placebo (Control)
Number of subjects: 10002

Group type: COMPARATOR
Intervention: Quadrivalent meningococcal conjugate vaccine (Control)
Number of subjects: 10002
Study: 33688020

Group type: EXPERIMENTAL
Intervention: RT + anti-PD-L1 + L19-IL2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RT + L19-IL2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Triple combinations (RT + anti-PD-L1 + L19-IL2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: RT + anti-PD-L1
Number of subjects: 0